Hangzhou Adcoris Biopharmacy

Executive Summary

Hangzhou Adcoris Biopharmacy is a private biotechnology company founded in 2014 and headquartered in Hangzhou, China. The company specializes in the discovery and development of innovative biologic drugs, primarily therapeutic antibodies and other protein-based modalities, targeting oncology and immunology indications. Leveraging cutting-edge engineering technologies, Adcoris aims to address high unmet medical needs by designing novel biologics with improved efficacy and safety profiles. As a preclinical-stage player with a lean team of 1–50 employees, the company operates in the competitive Chinese biopharmaceutical landscape but remains under the radar with no disclosed funding rounds or valuation. Its focus on antibody engineering suggests potential applications in immune checkpoint modulation or targeted cancer therapies. Given its early-stage nature, Adcoris has not yet advanced any candidate into clinical trials, and its pipeline remains undisclosed. The company's success hinges on progressing lead programs toward Investigational New Drug (IND)-enabling studies and securing funding or partnerships to support clinical development. Key risks include the inherent uncertainty of preclinical research, regulatory hurdles in China, and intense competition from more established biotech firms. However, if Adcoris demonstrates compelling preclinical proof-of-concept, it could attract collaboration opportunities with larger pharmaceutical companies seeking innovative biologics assets. The next 12–18 months will be critical for the company to achieve milestones that validate its technology platform and de-risk its pipeline.

Upcoming Catalysts (preview)

• Q1 2027IND Filing for Lead Antibody Candidate50% success
• H2 2026Presentation of Preclinical Data at Major Conference60% success
• Q3 2026Strategic Partnership or Licensing Deal40% success